Regenxbio Inc reports results for the quarter ended December 31 - Earnings Summary

• Regenxbio Inc RGNX.OQ reported a quarterly adjusted loss of $1.30​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of $-1.01. The mean expectation of twelve analysts for the quarter was for a loss of 96 cents per share. Wall Street expected results to range from $-1.65 to 43 cents per share.

• Revenue rose 43% to $30.34 million from a year ago; analysts expected $36.56 million.

• Regenxbio Inc's reported EPS for the quarter was a loss of $1.30​.

• The company reported a quarterly loss of $67.15 million.

• Regenxbio Inc shares had fallen by 36.5% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 14.6% in the last three months.​

• In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Regenxbio Inc is $29.00, about 68.5% above its last closing price of $9.14

This summary was machine generated from LSEG data March 5 at 03:12 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)